Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women between 18 and 75 years of age
- People who have been diagnosed with breast cancer that has spread or cannot be surgically removed, confirmed through a tissue or cell sample
- People who are planned to receive at least 2 cycles of a treatment regimen that includes the drug UTD1
- People who have little to no nerve problems in their hands, feet, or limbs before starting the trial (below a certain threshold on a standard medical scale)
- People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard health scale)
- People whose blood counts and organ function meet specific minimum levels when tested within 7 days before joining, including healthy levels of white blood cells, platelets, and red blood cells, without having received blood transfusions or certain blood-boosting medications very recently
- People whose kidney and liver function blood test results fall within acceptable ranges before joining
- People who are expected to live for at least 12 weeks
- People with no history of serious heart, lung, liver, kidney, or other major organ disease
- People who have signed a form giving their informed agreement to take part
- People who are willing and able to follow the trial's requirements throughout
- Women who could become pregnant must have had a negative pregnancy test within 14 days before joining, and must already be using reliable contraception and be willing to continue using it during the trial and for 8 weeks after it ends
Who may not be able to join:
- People who have previously been treated with the drug UTD1
- People who have a severe infection that is not under control
- People who have cancer that has spread to the membranes around the brain or spinal cord, brain spread causing symptoms, pressure on the spinal cord, or brain or membrane involvement detected on scans at the start of the trial — though people who completed local brain treatment at least 21 days before starting and have stable symptoms with no bleeding in the brain confirmed by imaging may still be considered eligible (confirm with trial site)
- People whose hands or feet are not suitable for wearing compression or cold gloves and socks used in the trial
- People who are unable to complete the nerve symptom questionnaires, including those who cannot read, or who have other neurological conditions that could affect the accuracy of nerve-related assessments
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ting Li, fudan university shanghai cancer center shanghai, China
Phone: 13816110335
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Difference in the incidence of ≥ grade 2 peripheral sensory neuropathy (CTCAE 5.0) after 2 cycles of UTD1 treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.